Media Reports

2022.02.03

Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection

Read at Endpoints

2021.07.09

FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations

Read at FierceBiotech

2021.05.19

2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

Read at Endpoints

2021.05.19

2021.5-FierceBiotech: ASCO: I-Mab’s checkpoint inhibitor drug helper uliledlimab sees early promise in Tecentriq cancer combo test

Read at FierceBiotech

2021.04.27

2021.4-Biocentury: I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline

Read at Biocentury

2021.04.15

2021.4-Biocentury: Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

Read at Biocentury

2021.03.11

2021.3-Biocentury: I-Mab signs first two deals of immuno-oncology discovery initiative

Read at Biocentury

2021.01.04

Endpoints: I-Mab —A Biotech on the Rise with Inspired Science

Read at Endpoints

2020.09.13

Nature BioPharma Dealmakers, September 2019: I-Mab Biopharma company profile

Read at Nature BioPharma Dealmakers

2020.09.05

2020.9-Biocentury: Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

Read at Biocentury